Longeveron(LGVN) - 2024 Q3 - Quarterly Results

Exhibit 99.1 LongeveronAnnounces Third Quarter 2024 Financial Results and Provides Business Update ● Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B in rare pediatric disease HLHS has achieved more than 80% enrollment ● Positive Type C meeting with U.S. FDA confirmed ELPIS II is pivotal and, if positive, acceptable for Biological License Application (BLA) submission for full traditional approval ● Positive data from the Phase 2a clinical trial (CLEAR MIND) evaluating Lomecel-B in Alzheimer's disease ...